Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to tenofovir alafenamide in chronic hepatitis B patients with suppressed HBV DNA on adefovir-containing regimens
ChiCTR1900027289Phase 4Not yet recruiting
- Sponsor
- Jumei Foundation
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Jumei Foundation. Primary endpoints: HBV DNA level at week 48, Renal function markers at week 48 and 1 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1900027289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027289.